Economic hardship and/or political turmoil stimulated migration of Trypanosoma cruzi -infected population from Latin American countries to the United States and Europe; originating cases of Chagas disease were transmitted through blood, organ donation, and vertical transmission. Hispanic immigrant women of reproductive age in the United States coming from Chagas disease-endemic countries accounted for 2, 384,644, and 5,841,538 in 1990 and 2000, respectively. Considering the prevalence rates for T. cruzi infection in their country of origin and the risk of newborns from infected mothers to acquire congenital infection as 1.33% and 5%, we estimated that the number of T. cruzi -infected newborns was 85-318 in 1990 and 166-638 in 2000. Diagnosis of infection in the mother and newborns at risk is needed. A high rate of cure is achieved, almost 100%, when the offspring is treated early. Health authorities, professional associations, physicians, and Hispanic groups should pay more attention to the subject.
INTRODUCTION
Chagas disease is a vector-borne disease that can also be transmitted by blood transfusion, organ transplant, or from mother to fetus. 1, 2 Congenital Chagas disease may cause abortion or premature birth, stillbirth, and low-birthweight babies; however, differences have not been observed between infected and uninfected mothers with respect to abortions, low birth weight, intrauterine deaths, and fetal development. 1 Until now, the majority of congenital cases were considered asymptomatic or olygosymptomatic. 1, 3 When symptoms are present in newborn babies, they appear soon after delivery; hepatosplenomegaly is the most common clinical finding. 1, 3, 4 However, case reports from Bolivia described that, after excluding most of other possibly associated pathologies, ~50% of infected newborns were symptomatic, with a mortality rate of 2-13%. 3, 4 Often, they were premature babies with low birth weight and hepatosplenomegaly. 3, 4 There is no specific clinical marker of congenital Chagas disease, 3 except the finding of parasites (trypomastigotes) in the blood. Transplacental infection may occur in different pregnancies of the same woman, whereas siblings of congenitally infected children may not be infected. In newborn twins, infection with Trypanosoma cruzi has been described in one or both. 1 Congenital Chagas disease has been reported from Argentina, Bolivia, Brazil, Chile, Colombia, Guatemala, Honduras, Paraguay, Uruguay, and Venezuela, 2 as well as from Mexico 5 and Peru. 6 The rate of congenital T. cruzi transmission varied from 0.75% to 7.1% in Argentina 1, [7] [8] [9] [10] [11] ; from 4% to 9.5% in Bolivia 1, 8, [12] [13] [14] ; from 1% to 10.5% in Brazil 1, 2, [15] [16] [17] ; from 0.49% to 19% in Chile 1, 8, 18 ; from 1.44% to 10% in Paraguay 8, 19, 20 ; and from 0.13% to 1.57% in Uruguay. 1 Several factors such as parasitemia in the mother, parasite strain, techniques used for diagnosis (microhematocrit, polymerase chain reaction [PCR] , histopathology, and/or serology) as well as methodologic aspects (target population [underweight newborns] or the time after delivery in which the sample for testing is obtained), may contribute to these variations on rates of congenital T. cruzi transmission. For instance in Paraguay, detection of parasites by microhematocrit concentration detected 2 (3%) newborns with congenital Chagas disease among 65 newborns delivered by T. cruzi -infected mothers, but another infected infant was detected by PCR in this group. In another location, only PCR detected 3 (10%) congenital cases at birth among 30 newborns from infected mothers. Overall, six babies from both locations were positive by PCR, and two were also positive by direct microscopy. None of the newborns were found to have IgM-specific antibodies against T. cruzi at birth. 19 Also in Paraguay, 20 (1.44%) of 1,381 babies were found to be infected by the microhematocrit technique, but this technique missed 77 cases that were later detected by other techniques. PCR were positive in 60 (7.4%) of 815 babies, and conventional serology by an EIA was positive in 89 (7%) of 1,248 babies 6 months after delivery. At the end, PCR and serology failed to diagnose seven and two cases, respectively, of the 104 infected babies. 20 It was estimated that ~12,000 new cases occurred through this mode of transmission in the endemic countries of the Americas in 1985 21 and 14,000 in 2005. 22 In fact, congenital Chagas disease has been found in every endemic country in which it was searched.
The continued migration from rural to urban areas in endemic countries results in large numbers of subjects infected with T. cruzi living in cities, including women of reproductive age, resulting in an urbanization of Chagas disease. 1 Beginning in the 1960s and continuing to the present, migration from endemic countries of Latin America to the United States and Europe resulted in the diagnosis of Chagas disease in non-endemic countries, 23 which increased during the 1990s and 2000s. 24 Chagas disease from blood and organ donation has been reported in Canada, 25 Spain, 26 and the United States. 27, 28 Vertical transmission has been described in Sweden, 29 Spain, [30] [31] [32] Switzerland, 33 and two possible autochthonous cases have been reported from the United States. 34 Because the United States is by far the largest recipient of immigrants from endemic countries, 23, 24 testing for Chagas disease in pregnant women is not required, and congenital transmission may be under-recognized, we estimated the potential risk of transmission of T. cruzi to children born to immigrant women from endemic countries and discuss its healthcare implications MATERIALS AND METHODS Source of data. Data were obtained from several sources as follows: number of Hispanic women living in the United States, born in Latin American-endemic countries for Chagas disease, as reported in the US Census in 1990 and 2000 35 ; fertility rates of Hispanic population for each state of the United States 36 ; overall prevalence of T. cruzi infection in each endemic country in 1980-1985 21, [37] [38] [39] ; and overall rate of congenital T. cruzi transmission in the Americas of 1.33%, as reported by the Regional Office of the World Health Organization 22 or 5% as reported in the literature. 1, 3, 20 Assumptions. For the calculations, it was assumed that maternal infectivity rate for T. cruzi in Hispanic immigrant women is (1) the same as the overall T. cruzi infection rate reported in the countries of origin (Argentina, Bolivia, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay, Peru, Uruguay, and Venezuela; reviewed in reference 21 and listed in the footnote of Table 1 ), as well as for Brazil, 37 and Mexico 38 for the 1980-1985 period. For Nicaragua, data from 2001 were used because it is the first nationwide prevalence rate available. 39 (2) The probability of transmitting T. cruzi from infected mothers to newborns was 1.33%, the overall rate of congenital T. cruzi transmission reported for the Americas, 22 or a 5% transmission rate as reported in the literature. 1, 3, 20 Estimates. To estimate the potential number of congenital T. cruzi infections in 1990 and 2000, the following formula was applied: N ( t ) pft , where N ( t ) is the number of women of Hispanic origin 15-44 years of age immigrating from the following endemic countries, Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico Nicaragua, Panama, Paraguay, Peru, Uruguay, and Venezuela, recorded in the 1990 and 2000 US Censuses 35 ; p is the maternal seroprevalence of T. cruzi infection (estimation based on the overall prevalence of T. cruzi infection in their country of birth 21, [37] [38] [39] ; f is the fertility rate for each state for 1990 and 2000, respectively 36 ; and t is the probability of transmitting T. cruzi to the newborn, 1.33% or 5%. This formula was applied to the Hispanic female population 15-44 years of age living in each state by country of birth. For instance, the estimated number of children with congenital T. cruzi infection born to the infected female population of 15-44 year olds born in Argentina and living in Texas equals 0.12: this was calculated as the number of women 15-44 years old born in Argentina and living in Texas [ N ( t ) = 1,275], multiplied by the overall prevalence for T. cruzi in Argentina ( p = 7.2%), multiplied by the Hispanic female fertility rate in Texas ( f = 104 per 1,000 women 15-44 years of age in Texas in 2000), multiplied by the probability of transmitting T. cruzi to the newborn ( t = 1.33% or 5%). This procedure was repeated for each of the above-mentioned countries and the US states. All data were rounded to the nearest hundredth of a unit using conventional methods.
RESULTS
The total number of Hispanic immigrant women 15-44 years of age coming from Chagas disease-endemic countries recorded in the 1990 and 2000 census were 2,384,644 and 5,841,538, respectively ( Table 1 ). In 1990, the number of estimated T. cruzi -infected Hispanic pregnant women was 61,107. Applying 1.33% and 5% transmission rates to the newborns delivered by the infected women, 85 and 318 newborns with congenitally acquired T. cruzi infection would be expected ( Table 1 ). In 2000, the number of expected T. cruzi -infected Hispanic pregnant women was estimated to be 12,755. Applying high and low T. cruzi transmission rates for this year, an occurrence of 166 and 638 newborns with congenitally acquired T. cruzi infection was estimated ( Table 1 ) . ( Table 3 ) .
DISCUSSION
The estimates obtained for 1990 and 2000 indicate that the expected number of congenital Chagas infections in the United States ranges from 85 to 638, depending on the prevalence rates in the country of origin of the Hispanic population, 21, [37] [38] [39] year of the data assessed, 35 maternal fertility rate, 36 and the probability of mother to child transmission. 1, 3, 20, 22 Methods to estimate prevalence and incidence using secondary data are approximate, and the estimates depend on the assumptions made. In this report, we assumed that the in 1990 belong to a population group that was born between 1945 and 1975, in those years, more members of this cohort were at higher risk of acquiring T. cruzi through vectorial or blood transmission than the one we are using in our estimates. Therefore, there might be an underestimation of the expected number of congenital cases. On the other hand, part of the population recorded in the census 2000 to whom we applied the overall prevalence rate of 1980-1985 were born at the end of this period and thus would have been exposed to lower risk, overestimating the expected number of congenital cases. Another potential source of error might be the assumption that the population who emigrated from each country to the United States had been exposed to the same risk as those left behind. T. cruzi infection is not evenly distributed among endemic countries nor in the same country, nor in the United States. For instance, information from Bolivia indicated that the seroprevalence in blood donors varies in different departments, from 51% in Santa Cruz, to 17% in Oruro, to 5% in La Paz. 40 In the United States, the number of T. cruzi -seropositive blood donors varies by location, depending on the number of people of Hispanic origin. 41 Lack of accounting for geographic variability (rural versus urban) and socioeconomic factors of the immigrants is likely to be biased in two ways. If a high proportion of the population that emigrated to the United States is coming from a rural poor area with a high prevalence rate of T. cruzi infection, the use of the overall prevalence in the country of origin would underestimate the proportion of infected women of reproductive age, and subsequently, the expected number of congenital cases. On the other hand, if most of the population that emigrates to the United States is coming from a non-endemic urban area of their countries, the reverse will occur; the real expected number of congenital cases will be overestimated. Unfortunately, the area (endemic or not for T. cruzi ) from the country of origin of the immigrants where the Hispanic women are from is unknown.
Recently, it was estimated that, of the 944,993 live births from Hispanic women, 3,780 were from T. cruzi -infected mothers and 189 of them gave birth to an infected newborn in 2004. 42 Calculations in that report were made under the assumption of a T. cruzi infection rate of 0.4% among Hispanic pregnant women 43 and 5% probability of the infected women delivering an infected child. 42 Our estimates for year 2000 using the same probability of transmission yielded an expected number of more than three times higher (189 versus 638) than the one estimated by Buekens and others. 42 We cannot compare our results with those reported by Buekens and others 42 because our estimation was done based on prevalence data of each of the endemic countries of origin for the immigrant population and was done using a prevalence rate reported for pregnant women in the US. However, it is worth noting that both estimations indicate that congenital transmission might be more important than is recognized in the United States. One question that arises is why, until now, only two possible congenital T. cruzi infection cases have been described in the United States. 34 One possible answer is that the number of congenital cases is in fact lower than the one we estimated, because the infected mothers are not submitted to re-infections and their parasitemia is lower. It has been reported that there is a relationship between higher parasitemia in the mother and the delivery of an infected child. 44 However, this possibility seems unlikely. In Latin America, cases of congenital T. cruzi infection have been detected in cities, where the infected mothers have not been exposed to the Triatominae vectors for years. Recent studies indicated that the population of T. cruzi is not homogeneous. There is agreement to group most of the clones into two group of lineages: T. cruzi I and T. cruzi II. T. cruzi I is linked to the sylvatic cycle and human disease in Central America and the Andean countries, and T. cruzi II in the Southern Cone countries is related to the domestic cycle and produces major infections and morbidity in humans. 45, 46 Because most immigrants in the United States are from Mexico and Central America, it may be possible that the T. cruzi I lineage infecting them is less able to produce congenital T. cruzi infection than the T. cruzi II lineage, which is more common in countries from the Southern cone, where most cases of congenital T. cruzi infection have been described. 1, 3, 4, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In addition, because neither the Hispanic pregnant women nor their newborns are screened for Chagas disease, it may also be possible that inexperienced health personnel miss the asymptomatic or oligosymptomatic cases and the symptomatic cases. The experience in Latin America shows that, when cases are being looked for, they are readily found.
Recognizing that congenital T. cruzi infection exists in the United States poses several challenges. First, health personnel need to know how to diagnose these cases. Only secondary prevention is practically possible. The identification of a child at risk requires the identification that the mother is infected. The country of origin of the mother may indicate her risk of being infected: Bolivia and Paraguay are the countries of origin with the highest risk as shown by the high prevalence of T. cruzi infection in those countries. 21 One way of identifying the infected mother requires a questionnaire that would include asking for the place of birth (country of origin and rural or urban area); housing characteristics (unsanitary conditions); and/or knowledge of the vector (positive recognition of Triatominae from a picture). This questionnaire may yield warning signs of a potential T. cruzi infection in the pregnant women or a way to make it unlikely. However, the questionnaire alone would not be suffice to rule out if the mother is a T. cruzi infected subject. To confirm infection, it would be necessary to carry out serology for T. cruzi. There are several commercial ELISA tests licensed by the FDA in the United States for that purpose. 47, 48 Treatment with the available drugs, nifurtimox or benznidazole, should generally be offered to reproductive age-infected non-pregnant women because there is some evidence of its efficacy. 49 Diagnosis in the infected newborn can be made by identifying parasites in cord blood using the microhematocrit concentration method or a variation of the Strout method (the microstrout). 1, 3, 8 Both are more sensitive than a fresh smear, but manipulation of live trypomastigotes requires special training to avoid spreading infection. 1 Another way to detect parasites is by using PCR. 2, 19, 50, 51 Although PCR reagents have been recently standardized and validated, they are not yet commercially available. 52 Specific IgMs have been found in newborns with transplacental T. cruzi infection. [53] [54] [55] However, anti-T. cruzi IgM testing have shown false-positive and false-negative results. 3 The finding of specific IgG antibodies by enzyme immunoassay (EIA) or any other conventional test (indirect immunofluorescence [IIF] or indirect hemagglutination [IHA]) in the newborn is of no use because the antibodies may have likely been transmitted from the mother. However, conventional serology such as EIA allows the diagnosis of congenital infection after the disappearance of maternally transmitted antibodies. There is consensus that antibodies passively transmitted from the mother should have disappeared in all infants 6-9 months after delivery. 3, 7, 8, 20 Therefore, a positive serology at that time with any combination of two accepted diagnostic tests would confirm a congenital Chagas case that requires immediate treatment. [1] [2] [3] Of course, the delay in confirming the diagnosis has the risk that a potentially infected child would not comply with a needed visit to the hospital 6-9 months after delivery, so the T. cruzi infection will remain undetected and untreated.
In the infected child, cure is almost 100% if the treatment is performed before 1 year of age with any of the two drugs currently available: nifurtimox or benznidazole. 2,3,8,10,19,20,51 None of them is licensed in the United States, but the CDC can provide them on request.
Difficulties and limitations for using estimates for policy decision are well recognized, and the figures presented here are an approximation of the problem, providing an overview of the potential risk for lack of diagnosis of congenital Chagas disease. Answering the challenges that represent congenital T. cruzi infection in the United States will require making federal and state regulatory agencies, health personnel, and their professional societies, as well as the Hispanic community, aware of the pros and cons of introducing a screening program for T. cruzi during pregnancy and the detection T. cruzi -infected newborns. In addition, it is recommended that research be carried out to generate critical data on the prevalence of T. cruzi infection on Hispanic pregnant women coming from Chagas-endemic countries and the development and validation of a questionnaire for mother screening.
